Global pharma drug delivery market to reach $2.5bn by 2029

Currently valued at $1.9 billion, the global pharmaceutical drug delivery market is expected to reach $2.5 billion by 2029, with a CAGR of 5.5%, according to a MarketsAndMarkets report.

The rising prevalence of chronic diseases, more pharma R&D investments, and government efforts to make drug delivery affordable are some of the key factors driving the market, the research found.

In addition, technological advancements, favorable reimbursement policies, and preferred home-based care will influence the market’s expansion.

Pharmaceutical drug delivery refers to methods, such as oral or injectable, that bring a therapeutic drug into the body of patients, targeting a specific area efficiently and safely.

The report also shared that the injectable drug delivery market will also account for the largest segment in the market based on route administration. With the increase of chronic diseases and self-administration technologies, injectables have become a preferred method for patients, offering easier treatment routines and better patient adherence.

However, looking ahead, the report noted that the risk of needlestick injuries and government pressure on pricing could add challenges to the market.

The leaders

Leading the global pharmaceutical drug delivery market is North America, which is estimated to reach $1.2 billion by 2029 at a CAGR of 5%, research showed.

“North America is predicted to hold the largest market share due to favorable reimbursement options and high healthcare expenditure.”

Additionally, the report found the Asia-Pacific region as the fastest growing regional market for drug delivery products, with China and India emerging as hotspots for market growth.

“Asia Pacific is expected to register the highest growth rate in the coming years, driven by the presence of leading pharmaceutical companies, a growing patient population with chronic conditions, increased healthcare spending, and government efforts to enhance access to pharmaceutical treatments in the region,” according to MarketsAndMarkets.

Drug delivery partnerships

The research firm noted that, as of 2023, key players in the pharmaceutical drug delivery market include Johnson & Johnson, Novartis, AbbVie, and Pfizer Inc., among others.

In August 2024, for example, drug delivery specialist Lindy Biosciences announced a licensing and collaboration agreement with Norvartis to advance self-administered drug treatments, using Lindy’s proprietary microglassification platform technology.

“This is a promising opportunity for us to collaborate with Lindy Biosciences and access their novel formulation technology, enhancing our capabilities to develop convenient regimens for select innovative medicines,” a Norvartis spokesperson told Access Insider.

“By advancing more self-administration options for healthcare practitioners and patients, we could significantly change their treatment experience for the better and reduce burden on healthcare systems.”

DepositPhotos/lightsource